Horizon Discovery Group plc Stock price

Equities

HZD

GB00BK8FL363

Pharmaceuticals

Delayed London S.E. 5-day change 1st Jan Change
- GBX -.--% Intraday chart for Horizon Discovery Group plc -.--% +23.00%
Sales 2018 58.73M 74.21M Sales 2019 58.25M 73.6M Capitalization 226M 285M
Net income 2018 -35M -44.22M Net income 2019 -4M -5.05M EV / Sales 2018 4.02 x
Net cash position 2018 26.74M 33.79M Net cash position 2019 6.56M 8.29M EV / Sales 2019 3.76 x
P/E ratio 2018
-7.31 x
P/E ratio 2019
-49 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 83.27%
More Fundamentals * Assessed data
Dynamic Chart
Medical Device Innovation Consortium Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics CI
Horizon Discovery : Acquisition by PerkinElmer Completes MT
PerkinElmer (UK) Holdings Ltd. completed the acquisition of Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others. CI
Horizon Discovery : Takeover by PerkinElmer Gets Court Approval MT
Horizon Discovery : Soars 110% on Acquisition by PerkinElmer in $366 Million Deal MT
PerkinElmer (UK) Holdings Ltd. agreed to acquire Horizon Discovery Group plc from Inclusive Capital Partners, L.P. and others for approximately £290 million. CI
Transcript : Horizon Discovery Group plc, H1 2020 Earnings Call, Aug 17, 2020
Horizon Discovery Group plc Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Horizon Discovery Group plc Announces the Addition of Single Cell RNAseq-Linked Pooled CRISPR Screening to Its CRISPR Screening Services Portfolio CI
Horizon Discovery Group plc Licenses Chosource Platform to TrueBinding, Inc for Development and Commercialization of Multiple Biotherapeutics CI
Transcript : Horizon Discovery Group plc - Analyst/Investor Day
Horizon Discovery Group plc Provides Group Revenue Guidance for the Six Months Ended June 30, 2020 CI
Horizon Discovery Group plc Introduces Cas9 and dCas9-VPR Stable Cell Lines to Simplify and Accelerate CRISPR Gene Editing Workflows CI
Rentschler Biopharma Licenses Horizon Discovery's Chosource Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins CI
Horizon Discovery Group plc Announces Board Changes CI
More news
Managers TitleAgeSince
Chief Operating Officer - 16-12-31
Sales & Marketing - -
Human Resources Officer - 19-06-30
Members of the board TitleAgeSince
Director/Board Member 60 20-12-22
Director/Board Member 36 21-06-29
Director/Board Member 49 22-02-27
More insiders
Horizon Discovery Group Ltd, formerly known as Horizon Discovery Group PLC, is a United Kingdom-based life science company. The Company drives the application of gene editing and gene modulation. It offers a portfolio of tools and services to help scientists understand gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
More about the company
  1. Stock
  2. Equities
  3. Stock Horizon Discovery Group plc - London S.E.